Nasal Polyps
|
0.100 |
Biomarker
|
disease |
BEFREE |
At this time, while there are no FDA-approved biologics for use in NP, research has highlighted the contributions of IL-4, IL-5, IL-13, and IgE as disease mediators in the pathogenesis of NP.
|
31073812 |
2019 |
Nasal Polyps
|
0.100 |
Biomarker
|
disease |
BEFREE |
MUC5AC and MUC5B secretions were significantly increased in IL-4- or IL-13-primed, but not IL-5-primed fragments of nasal polyps.
|
29802623 |
2019 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, the stimulation of cultured epithelial cells with Th2 cytokines, IL-4 and IL-5, resulted in an upregulation of CCL17 expression only in NP epithelial cells whereas the expression of CCL17 was increased in both normal epithelial cells and NP epithelial cells by Th1 cytokines.
|
29746583 |
2018 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, IL-17RB and ST2 expressions on mDCs were correlated with the IL-5 mRNA level as well as eosinophil number in NP.
|
30519393 |
2018 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Each is also associated with significantly distinct host immune responses; DSI, II, and III(b) invoked a variety of pro-inflammatory, T<sub>H</sub>1 responses, while DSIII(a), which exhibited significantly increased incidence of nasal polyps (Fisher's exact; p = 0.034, relative risk = 2.16), primarily induced IL-5 expression (Kruskal Wallis; q = 0.045).
|
28494786 |
2017 |
Nasal Polyps
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
|
28918644 |
2017 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated the association of postoperative endoscopic findings with clinical parameters, mucosal eosinophil count and mRNA expression of CCL11, IL-5, and IFN-gamma in nasal polyps.
|
26987817 |
2016 |
Nasal Polyps
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows for the first time that IL-9 is involved in EO homeostasis in CRSwNP and could explain the low benefit of anti-IL-5 therapy for some patients with asthma and nasal polyposis.
|
25704963 |
2015 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, we found that IL-33 induced upregulation of IL-5 by memory CD4(+) T cells isolated from nasal polyps of patients with eosinophilic chronic rhinosinusitis.
|
25692703 |
2015 |
Nasal Polyps
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since, TM-IL-5Ralpha is down-regulated and SOL-IL-5Ralpha (antagonistic) is upregulated in NP tissue, our findings are important to understand the clinical trials with anti-IL-5 in humans.
|
19170670 |
2009 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of DP and CRTH2 in nasal polyps (NP) and uncinate process mucosae (UPM) was examined by in situ hybridization and immunohistochemistry and evaluated by real-time quantitative PCR. h-PGDS, IL-5, eotaxin and RANTES expression was also determined.
|
18802357 |
2009 |
Nasal Polyps
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, increased levels of IFN-gamma, IL-4 and IL-5 and decreased levels of IL-10 and TGF-beta were found in nasal polyps.
|
19639723 |
2009 |
Nasal Polyps
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that GM-CSF, IL-5 and RANTES are produced in increased amounts in both allergic and non-allergic NP.
|
9761019 |
1998 |